Introduction
Current development of human health related studies requires a growing number of elements to be monitored in biological matrices, including all essential and well-recognized toxic metals. Cobalt is an essential element in the human body as a component of vitamin B12 and it is clear that monitoring of body fluids for cobalt is essential for the control of nutritional deficiencies and perhaps prevention of its toxic effect in cases of occupational exposure. The most serious problems of cobalt determination in serum and urine samples are: (i) the extremely low concentration of this element in body fluids (normal serum and urine levels are in the range 0.1-0.5 µg L -1 ); (ii) possible sample contamination during blood collection; (iii) high content of organic matrix causing numerous physical and chemical interferences. Double focusing sector field inductively coupled plasma mass spectrometry is a very useful and superior technique for this analysis. However, these instruments are not available in all laboratories. Another option is to use electrothermal atomic absorption spectrometry. Therefore an accurate measurement of cobalt at concentrations 0.5-1 µg L -1 is still a challenge. In the present study, the possibilities of electrothermal atomic absorption spectrometry (ETAAS) are investigated for Co determination in serum and urine samples from healthy persons and patients on haemo dialysis. The originality of the paper is that procedures based only on direct determination of Co without any preliminary sample pretreatment are proposed. This makes it possible to achieve very low detection limits due to the very low blank sample level. The methods of direct determination and the procedures of extractive separation of cobalt from serum have been optimized (type of graphite tube, modifier, temperature programs and calibration procedure). Analytical quality assurance of the method was carried out by analyzing standard reference materials.
Experimental

Instrumentation
The atomic absorption spectrometer Varian Spectra AA 640Z Zeeman AAS equipped with GTA100 graphite furnace (Varian, USA) and PSD-100 autosampler (Varian) was used. Pyrocoated tubes and tubes with centre fixed platforms were used as atomizers. A Varian cobalt hollow cathode lamp was used and the measurements were performed at 242.5 nm. Argon was applied as protective gas and 10µl serum or urine samples were injected into the graphite furnace (GF). The graphite furnace operating parameters are presented in table 1. Only integrated absorbance values (peak area) were used for quantification. Serum and urine samples were obtained from 20 presumably healthy volunteers and additional serum samples were obtained from 15 dialyzing patients and were transferred into plastic tubes. Serum samples were collected with a plastic iv canula No. 24 with injection valve. Urine samples were taken as spot samples. The samples were acidified up to pH 2 and were kept frozen (-18°C) until analysis.
Reagents and samples
All patients signed agreement for cobalt testing of their serum during a systematic medical checkup.
Procedures
Co direct ETAAS determination in serum and urine. The serum or urine samples of 10 µl were directly introduced into the graphite furnace together with equal volume of modifiers. Calibration curves (1-5 µg L -1 Co) were prepared by using aqueous standard solutions of Co.
Extraction-ETAAS determination of Co in serum
Extraction of Co as chelate complex with APDC. Serum sample (3.0 ml) was placed in the extraction tube, 1 ml 1% solution of APDC was added and extraction was performed for 3 min in 500 µl IBMK. Cobalt was measured in the organic phase by ETAAS. Extraction of Co as ion associate complex with NH 4 SCN. Serum sample (5.0 ml) was placed in the extraction tube, 0.2 g NH 4 SCN and 0.05 g NH 4 F were added and extraction was performed for 3 min in 500 µl IBMK. Cobalt was measured in the organic phase by ETAAS. Recoveries for both procedures were calculated against organic standard solutions of Co. 
Results and discussion
ETAAS determination of Co in serum and urine GFAAS program optimization.
Serum and urine samples were spiked with 4 µg L -1 Co, ashing and atomization curves were constructed for both atomizers investigated in the presence of the modifiers studied. The results obtained are presented in figure 1 . It was found that ash temperature of 1200°C for pyrocoated tubes and 1300°C for tubes with centre fixed platforms can be used without any loss of Co even in the absence of a modifier. These temperatures are high enough to ensure complete matrix decomposition and removal during the pyrolysis step. The modifiers used do not influence the thermal behaviour of Co. The only advantage achieved with H 2 O 2 as modifier is the elimination of carbon residue formed at the end of the atomization cycle. It is very important to keep the atomization temperature as low as possible, because a rise in the atomization temperature leads to higher values of nonspecific absorption: for pyrocoated tubes the optimal atomization temperature is around 2100°C and for tubes with centre fixed platform around 2300°C. The optimal instrumental parameters for Co determination in serum and urine are summarized in table 1. Calibration. Matrix interferences were evaluated according to the slopes of calibration curves obtained in the presence of the matrix (serum or urine), and for aqueous standard solutions. The results obtained are recorded in table 2. As can be seen, tubes with centre fixed platforms are perfect atomizers for Co determination in urine -the slope of aqueous standard calibration curve (3.9 ± 1.2%) and the slope of the calibration curve in presence of urine (3.8 ± 1.4%) are practically equal. This means that calibration against aqueous standard curves could be used, simplifying in this way the analytical procedure. Pyrocoated tubes are preferable atomizers for serum samples, but in this case significant differences were observed between the slopes of the calibration curves for aqueous standards (3.8 ± 1.2%) and in the presence of serum (2.5 ± 2.0%). The standard addition method was applied for calibration. However, further experiments performed showed that no significant differences were found between the slopes of calibration curves for different serum samples; consequently, the analytical procedure requires at least a single standard addition to one of the serum samples analyzed. It should be mentioned that statistically different slopes of the standard addition curves were obtained when standard solution was added beforehand to the sample and then injected into the furnace and for the standard additions made directly into the graphite furnace by using the facilities of the auto sampler. In the former case, the slope was remarkably higher. Depression of Co atomization was probably due to the formation of some complexes with serum components; this requires standard addition before sample injection. The accuracy of the proposed procedure for ETAAS determination of Co in serum and urine samples was checked by spike recovery experiments. Serum and urine samples were spiked with Co in The accuracy of the analytical methods developed was also checked by analyzing certified reference materials for urine and serum. A comparison of the results given in table 3 shows good agreement with the certified values, i.e. the validity and versatility of the analytical procedure is confirmed.
Extraction-ETAAS determination of Co in serum
Since cobalt content in some serum samples is lower than the determination limit achieved by ETAAS, the separation and preconcentration procedures should be proposed for these samples. Liquid/liquid extraction was tested as an effective analytical procedure for Co preconcentration directly from undigested serum samples. Two extraction reagents were studied for this purpose. Ammonium pyrrolidinedithiocarbamate (APDC). This reagent forms chelate complexes with Co and ensures quantitative extraction of Co in a wide pH range from 4 to 7. Recoveries achieved for extraction of Co with APDC from 3 ml serum samples into 500 µl IBMK are in the range 95-97%, which means that this extraction system could be used for Co separation and preconcentration from serum samples. However, in some cases relatively high values of non-specific absorption were observed during the ETAAS measurement due to the high iron content co-extracted in the organic phase. To eliminate these interferences another extraction procedure was suggested. (table  3) for reference standard samples confirmed the accuracy of the proposed preconcentration method.
Analytical application
The analytical methods developed were applied to the determination of Co in serum and urine (direct method and extraction method with NH 4 SCN for a low concentration of Co) samples obtained from 20 presumably healthy volunteers and in serum samples from 10 patients on dialysis. The results obtained revealed that the Co content in serum of healthy volunteers varied in the range 0.04 to 0.09 µg L -1 and in urine in the range 0.11 to 1.22 µg L -1 . As could be expected, the Co content in the serum samples of persons on dialysis was significantly higher than in healthy persons, with serum Co ranging from 1.70 to 4.70 µg L -1 .
Conclusions
The results of this study indicate that direct ETAAS determination of cobalt in serum and urine samples is possible in the range 0.2-30 µg L -1 by using graphite tubes with a centre fixed platform for urine samples and pyrolytically coated graphite tubes for serum samples. The suitable modifier proposed is H 2 O 2 , which prevents carbon residue formation in the graphite tube. Pretreatment temperature of 1200°C (1300°C) and atomization temperature of 2100°C (2300°C), respectively, for pyrolytically coated graphite tubes and graphite tubes with centre fixed platforms are recommended. For serum samples with a cobalt content below 0.2 µg L -1 , the extraction procedure with NH 4 CSN, in the presence of NH 4 F as a masking reagent for iron, into IMBK was developed. ETAAS measurements were carried out using the same temperature program.
